Key Market Indicators
The sales of diabetes medicine in the Czech Republic are set to reach $406 million by 2026, up from $348 million in 2021. This is an average year-on-year growth of 2.7%. Since 1995, the Czech market has increased by an average of 9.1% year-on-year. The country ranked ninth in 2021, with Portugal taking the lead with $348 million. Canada, Spain and Italy ranked second, third and fourth respectively. Czech insulin imports are expected to reach $200.6 million in 2026, up from $174.1 million in 2021. This is an average year-on-year growth of 2.5%. Since 1998, Czech demand has increased by 4.8% year-on-year. Czech insulin exports are set to reach $80.6 million by 2026, up from $66.8 million in 2021. This is an average year-on-year growth of 3.2%. Since 1998, Czech supply has increased by 1.4% year-on-year. The country was ranked tenth in 2021, with Belgium coming ahead with $66.8 million. France, Italy and China were respectively ranked second, third and fourth.
